Table 1.
Summary of studies on organosilicon nanocarrier conjugates with platinum drugs.
| Platinum Drug | Organosilicon Nanocarrier | Other Ligand/Carrier/Drug | Targeting Ligand | Cell Line/IC50 | Size (nm) | Refs. |
|---|---|---|---|---|---|---|
| cisPt(IV) | polysilsesquioxane system | PEG | A549/14.91 μM NCI-H460/2.07 μM |
150.3 ± 5 | [18] | |
| cisPt(IV) | MNS | mPEG2k | lactose (LA) | HepG-2/10.46 μM normal fibroblast L929 cells |
- | [22] |
| cisPt(IV) | MNS | FITC | HeLa/0.22 μM A549/1.07 μM MCF-7/0.38 μM |
~2 nm | [38] | |
| cisPt(IV) | MSGNR | β-cyclodextrin, AlPcS4, Ad-PEG, Ad-LA | HepG2 COS7 normal cells |
~14 nm (MSGNR) | [42] | |
| cisPt(IV) | UCNPs@SiO2 | bridge peptide sequence (KKKKKC), oligo(ethyl glycol) (dPEG6) | A2780 A2780cis |
- | [44] | |
| hydrated cisplatin prodrugs | MSN | polyacrylamide, doxorubicin |
HeLa/0.208 μM(24 h) A357/<0.080 μM(24 h) |
291 nm | [46] | |
| cis-diaquadiamino platinum(II) | mesoporous magnetic silica nanoparticles | A2780 | 225 ± 23 nm | [49] | ||
| cis-diaquadiamino platinum(II) | CoFe2O4 encapsulating silica NPs | rhodamine isothiocyanate (RITC) | folic acid (FA) | HeLa (FR+Ve)/3.0 μg/mL HaCat (FR−ve)/4.6 μg/mL 3T3/7.2 μg/mL |
96 nm | [50] |
| oxaliplatin | MSN-COOH | HepG-2 | [51] | |||
| cisplatin | Fe3O4@SiO2@Au NPs | SW480 SW620 |
below 40 nm (Fe3O4@SiO2@Au) | [52] |